148 related articles for article (PubMed ID: 30782771)
1. Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis.
Claydon J; Popescu CR; Shaiba L; Christopherson C; Human D; Taylor R; Solimano A; Lavoie PM
CMAJ Open; 2019; 7(1):E88-E93. PubMed ID: 30782771
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
Garegnani L; Styrmisdóttir L; Roson Rodriguez P; Escobar Liquitay CM; Esteban I; Franco JV
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013757. PubMed ID: 34783356
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
Claydon J; Sur A; Callejas A; Ladd M; Kwan E; Taylor R; Turvey SE; Solimano A; Lavoie PM; Marr N
PLoS One; 2017; 12(4):e0176152. PubMed ID: 28437470
[TBL] [Abstract][Full Text] [Related]
8. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
9. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
10. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
11. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
La Via WV; Notario GF; Yu XQ; Sharma S; Noertersheuser PA; Robbie GJ
Pulm Pharmacol Ther; 2013 Dec; 26(6):666-71. PubMed ID: 23523663
[TBL] [Abstract][Full Text] [Related]
12. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.
Alexander PM; Eastaugh L; Royle J; Daley AJ; Shekerdemian LS; Penny DJ
J Paediatr Child Health; 2012 May; 48(5):395-401. PubMed ID: 22720323
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
15. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
[TBL] [Abstract][Full Text] [Related]
18. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
19. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
